Muscle Matters: The Next Frontier of Obesity Medicine
5 mins to read
July 8, 2026
The obesity field has spent years focused on how much weight patients can lose. As powerful new medicines transform obesity treatment, a new clinical question is coming into focus:
How do we ensure that weight loss does not come at the expense of muscle?
Muscle is a key metabolic organ that plays a central role in insulin sensitivity, energy expenditure, physical function, and healthy aging. As GLP-1-based therapies become more widespread, muscle preservation is emerging as an increasingly important consideration for patients, physicians, and drug developers alike.
While muscle preservation is relevant for all patients, some groups may be especially vulnerable to the consequences of muscle loss:
Older Adults
People over 65 already experience age-related declines in muscle mass and strength. Additional muscle loss during weight reduction may accelerate functional decline, increasing the risk of falls, frailty, and loss of independence. Recent studies have raised concerns that prolonged GLP-1 treatment may be associated with declines in muscle function in older adults, particularly those already vulnerable to sarcopenia and frailty.
Patients with Type 2 Diabetes
Skeletal muscle plays a central role in metabolic health, serving as a major site of glucose uptake and utilization. Because muscle metabolism is often impaired in patients with Type 2 Diabetes, preserving muscle mass may be especially important in this population. Weight loss associated with GLP-1 treatment can challenge the maintenance of muscle mass, particularly when nutritional intake and physical activity are inadequate. Emerging research suggests that GLP-1-associated reductions in lean mass may affect physical function – including gait speed and grip strength – in some patients with diabetes, highlighting the importance of monitoring muscle health alongside traditional metabolic outcomes.
Children and Adolescents
Children and adolescents represent another population deserving careful consideration. During growth, the formation of muscle and bone is essential for long-term health. As GLP-1 therapies are increasingly used in younger patients, researchers are studying their effects on body composition and musculoskeletal development, including whether reductions in lean mass could have implications for long-term bone health in females.
Why this matters
These populations represent a large proportion of patients receiving GLP-1 therapies, making muscle preservation an increasingly important consideration in obesity care.
The obesity field has made remarkable progress in helping patients lose weight. The next challenge is understanding how to achieve meaningful weight loss while preserving muscle and physical function. As weight loss goals continue to evolve, preserving strength, mobility, and whole-body metabolic function will become just as important as the number on the scale.
For additional discussion of this topic, see Prado et al., "Muscle matters: the effects of medically induced weight loss on skeletal muscle" (The Lancet Diabetes & Endocrinology).